<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264901</url>
  </required_header>
  <id_info>
    <org_study_id>NN304-1720</org_study_id>
    <nct_id>NCT00264901</nct_id>
  </id_info>
  <brief_title>Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes</brief_title>
  <acronym>PREDICTIVE™</acronym>
  <official_title>Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir® (Insulin Detemir [rDNA Origin] Injection) (PREDICTIVE™ 303)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America (USA). This trial aims for a
      comparison of the safety and efficacy in subjects with type 2 diabetes using either self
      titration or physician guided titration according to the local standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the change from baseline to end of treatment</measure>
    <time_frame>after 26 weeks in the value of laboratory-measured HbA1c between the self adjustment versus the standard of care group</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneously reported adverse events during the trial</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypoglycaemic during the trial nocturnal (11 pm - 6 am)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG during the trial (central laboratory) at Visit 2 and Visit 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving HbA1C &lt;= 7.0% at Visit 2 and Visit 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin detemir doses at Visit 2 and Visit 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject variation of before-breakfast SMPG values at Visit 2 and Visit 3</measure>
  </secondary_outcome>
  <enrollment type="Actual">5652</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes HbA1C &lt;= 12.0% within the past 12 months;

          -  BMI &lt;= 45.0 kg/m2

          -  Initiation, addition of, change to, or continuation of basal insulin therapy with
             insulin detemir as deemed necessary by Investigator

        Exclusion Criteria:

          -  Anticipated change in concomitant medication known to interfere with glucose
             metabolism such as systemic steroids, non-selective beta-blockers or mono amine
             oxidase (MAO) inhibitors.

          -  Proliferative retinopathy or maculopathy that has required acute treatment within the
             last 6 months.

          -  Any glucose lowering medication that is not indicated in combination with insulin,
             such as GLP-1 Analogues

          -  Known hypoglycemia unawareness or recurrent major hypoglycemia, as judged by the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plainsboro</city>
        <state>New Jersey</state>
        <zip>08536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007 Nov;9(6):902-13.</citation>
    <PMID>17924873</PMID>
  </results_reference>
  <results_reference>
    <citation>Selam JL, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin. 2008 Jan;24(1):11-20.</citation>
    <PMID>18021495</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhargava A, Chan V, Kimball ES, Oyer DS. Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study. Drugs Aging. 2016 Feb;33(2):135-41. doi: 10.1007/s40266-016-0342-9.</citation>
    <PMID>26833348</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2005</study_first_submitted>
  <study_first_submitted_qc>December 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2005</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

